BDI appoints VP of Business Development from Beckman Instruments.PITTSBURGH--(HealthWire)--Oct. 8, 1996--Biological Detection, Inc. (BDI BDI Burundi (ISO Country code) BDI Beck Depression Inventory BDI Belief-Desire-Intention (AI agents) BDI Baltic Dry Index BDI Basic Driver Improvement (traffic school) ) announced today the appointment of William T. Robinson as Vice President of Business Development. Mr. Robinson was most recently the Manager of Business Development for Beckman Instruments where he defined the strategic directions for the product group that included products for drug discovery, protein sequencing, DNA sequencing DNA sequencing The determination of the sequence of nucleotides in a sample of DNA. , DNA synthesis DNA synthesis commonly refers to:
HPLC high performance liquid chromatography. HPLC High-performance liquid chromatography Lab instrumentation A highly sensitive analytic method in which analytes are placed and chromatography software. Mr. Robinson was trained as a chemist and attended the Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. Executive Management Program. He has been responsible for developing strategic directions, as well as negotiating strategic alliances and acquisitions in these areas for the last 16 years. "Bill Robinson brings great experience in converting technological developments into business opportunities in the biotechnology industry. His recent focus on the drug discovery market will have a major impact on our strategic activities in this market" said D. Lansing Taylor, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BDI. BDI is developing and commercializing high precision and high throughput screening tools for the drug discovery market based on cell screens using fluorescence-based reagents, novel detection instrumentation, existing, as well as miniaturized array technologies and informatics. BDI recently announced a strategic alliance with Carl Zeiss Gmb that included an investment from Zeiss to develop the optical/mechanical systems required for drug discovery. The company is creating commercial and R&D partnerships that will make BDI the leader in cell-based, high precision and high throughput screening. CONTACT: Biological Detection, Inc. Karen Skurcenski, 412/826-3857 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion